DelveInsight’s, “Major Depressive Disorder Pipeline Insight, 2023,” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Major Depressive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Major Depressive Disorder Emerging drugs, the Major Depressive Disorder pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Major Depressive Disorder pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Major Depressive Disorder Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Major Depressive Disorder clinical trials studies, Major Depressive Disorder NDA approvals (if any), and product development activities comprising the technology, Major Depressive Disorder collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Major Depressive Disorder Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Major Depressive Disorder Pipeline landscape @ Major Depressive Disorder Pipeline Outlook Report
Major Depressive Disorder Overview
Major Depressive Disorder (MDD), also referred to as clinical depression, is a significant medical condition that can affect many areas of your life. It impacts mood and behavior as well as various physical functions, such as appetite and sleep. The exact cause of MDD isn’t known. However, there are several factors that can increase the risk of developing the condition.
Recent Developmental Activities in the Major Depressive Disorder Treatment Landscape
For further information, refer to the detailed Major Depressive Disorder Drugs Launch, Major Depressive Disorder Developmental Activities, and Major Depressive Disorder News, click here for Major Depressive Disorder Ongoing Clinical Trial Analysis
Major Depressive Disorder Emerging Drugs Profile
SAGE-217 is an investigational, oral, novel medicine in development for depression. SAGE-217 is an investigational oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM). The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), and contributes significantly to regulating CNS function. Biogen and Sage Therapeutics have submitted a new drug application (NDA) to the FDA for zuranolone for the treatment of major depressive disorder (MDD).
REL-1017, an NCE and novel NMDAR channel blocker with a preference for hyperactive channels associated with MDD. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for REL-1017 as an adjunctive treatment of MDD. REL-1017, has entered its Phase 3 registration program as an adjunctive treatment for MDD.
Seltorexant is an innovative selective orexin 2 receptor antagonist under development for the treatment of insomnia and related mood disorders. Insomnia is the repeated difficulty with sleep initiation, maintenance or quality that occurs despite adequate time and opportunity for sleep, resulting in daytime impairment. The clinical trials are being carried out for the treatment of major depressive disorder in phase III stage of development.
SP-624 is being studied in phase II stage of development for the treatment of major depressive disorder in comparison with placebo by Sirtsei Pharmaceuticals, Inc.
SPL026 (DMT), is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects. DMT is differentiated by its short psychedelic experience (< 30mins), which allows for short treatment sessions and offers the potential for convenient supervised treatments within patient clinics. Small Pharma is advancing a pipeline of DMT-based therapies and is leading the world’s first DMT clinical trial for depression, in collaboration with Imperial College London.
PDC-1421 (BLI-1005) is a Norepinephrine plasma membrane transport protein inhibitor being developed by BioLite Inc, for the treatment of major depressive disorder. The drug is currently in phase II stage of development.
Major Depressive Disorder Pipeline Therapeutics Assessment
There are approx. 75+ key companies which are developing the therapies for Major Depressive Disorder. The companies which have their Major Depressive Disorder drug candidates in the most advanced stage, i.e. Preregistration include SAGE Therapeutics.
Find out more about the Major Depressive Disorder Pipeline Segmentation, Therapeutics Assessment, and Major Depressive Disorder Emerging Drugs @ Major Depressive Disorder Treatment Landscape
Scope of the Major Depressive Disorder Pipeline Report
Dive deep into rich insights for drugs for Major Depressive Disorder Pipeline Companies and Therapies, click here @ Major Depressive Disorder Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Major Depressive Disorder Mergers and acquisitions, Major Depressive Disorder Licensing Activities @ Major Depressive Disorder Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/